10x Genomics (TXG) Misses Q1 EPS by 9c, Revenues Miss

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.22), $0.09 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $71.91 million versus the consensus estimate of $73.42 million.

“We are doing all we can to support our customers as they race to understand and fight the COVID-19 pandemic,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “Despite the temporary uncertainty in the macro environment, we see tremendous opportunities ahead. Our mission to accelerate the mastery of biology is more important now than it has ever been, and I am confident that the future holds an even greater appreciation and appetite for scientific discovery.”

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• Hyperscale Data plans special Class B stock dividend for shareholders